Mahroum, NaimÖzkan, Mehmet FatihAbalı, TunahanYılmaz, MesutBragazzi, Nicola Luigi2023-01-062023-01-062023Mahroum, N., Özkan, M. F., Abalı, T., Yılmaz, M. ve Bragazzi, N. L. (2023). Infectious side effects of baricitinib: A big data analysis based on VigiBase. Autoimmunity Reviews, 22(1). https://dx.doi.org/10.1016/j.autrev.2022.1032151568-99721873-0183https://dx.doi.org/10.1016/j.autrev.2022.103215https://hdl.handle.net/20.500.12511/10255Dear Editor, Baricitinib (known as “Olumiant”), is an inhibitor of Janus- associated kinase 1 and 2 (JAK1 and JAK2) initially introduced for the treatment of rheumatoid arthritis (RA), and later for systemic lupus erythematosus (SLE), and atopic dermatitis [1]. The first approval of baricitinib was from the European Medicines Agency (EMA) as a mon- otherapy or combination therapy with methotrexate for patients with RA unresponsive to disease-modifying anti-rheumatic drugs (DMARDs)eninfo:eu-repo/semantics/openAccessBaricitinibJAK InhibitorsRheumatoid ArthritisHerpes ZosterOral HerpesLetter22110.1016/j.autrev.2022.103215Q10009111064000012-s2.0-8514463727336270598Q1